Table 2.
Univariate and multivariate analyses of overall survival.
| Characteristic | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | ||
| Age | ≤60/>60 | 1.245 (0.625–2.856) | 0.156 | ||
| Sex | Female/male | 0.653 (0.302–1.127) | 0.129 | ||
| Tumor site | Head/body/tail | 0.936 (0.648–1.582) | 0.832 | ||
| Tumor size (cm) | ≤5/>5 | 1.925 (1.056, 3.559) | 0.046 | 1.369 (0.625, 2.848) | 0.521 |
| Tumor volume (cm3) | ≤37/>37 | 2.486 (1.245–4.325) | 0.009 | 2.675 (1.230–7.215) | 0.035 |
| Local recurrence | ≤6 mo/>6 mo | 3.522 (1.362–7.023) | 0.006 | 0.542 (0.308–2.034) | 0.384 |
| WBC (×109) | ≤10/>10 | 1.352 (0.475–2.322) | 0.789 | ||
| HGB (g/L) | ≤120/>120 | 1.086 (0.365–1.458) | 0.426 | ||
| PLT (× 109) | ≤300/>300 | 1.335 (0.468–3.589) | 0.459 | ||
| ALT (U/L) | ≤40/>40 | 0.895 (0.257–1.752) | 0.658 | ||
| AST (U/L) | ≤40/>40 | 0.235 (0.128–1.329) | 0.457 | ||
| ALP (U/L) | ≤100/>100 | 0.965 (0.042–1.436) | 0.689 | ||
| CA19-9 level | ≤35/>35 | 1.350 (0.618–3.572) | 0.245 | ||
| Complications | Yes/no | 0.621 (0.321–1.126) | 0.096 | ||
| IRE | With/without GEM | 0.389 (0.178–0.952) | 0.045 | 0.422 (0.157–0.958) | 0.007 |
IRE: irreversible electroporation; GEM: gemcitabine; HR: hazard ratio; WBC: white blood cell count; HGB: hemoglobin; PLT: platelet count; ALT: alanine transaminase; AST: aspartate aminotransferase; ALP: alkaline phosphatase; CA19-9: carbohydrate antigen 19-9.